Eli Lilly has received FDA approval for a combo pill called Symbyax to be used for the treatment of treatment-resistant depression.
Symbyax, which combines the ingredients of the antipsychotic Zyprexa (olanzapine) with the antidepressant Prozac (fluoxetine), is approved for patients with major depression who have not responded to two separate trials of different antidepressants.
It was originally approved by the FDA in 2003 for the treatment of bipolar disorder and is now the first medication approved for the treatment of treatment-resistant depression.
Lilly has also updated the labels for Symbyax and Zyprexa to include information about weight gain, hyperglycemia and hyperlipidemia following the FDA’s review of clinical trial data submitted between August 2007 and July 2008.
More information about Sybyax is available through the official Symbyax website.
depression.about.com
|
no comment untill now